Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 2000 May 15;348(Pt 1):159–166.

Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2.

G H Goodfellow 1, J M Dupret 1, D M Grant 1
PMCID: PMC1221049  PMID: 10794727

Abstract

The human arylamine N-acetyltransferases NAT1 and NAT2 catalyse the acetyl-CoA-dependent N- and O-acetylation of primary arylamine and hydrazine xenobiotics and their N-hydroxylated metabolites. We previously used a panel of recombinant NAT1/NAT2 chimaeric proteins to identify linear amino acid segments that have roles in imparting the distinct catalytic specificities to these proteins [Dupret, Goodfellow, Janezic and Grant (1994) J. Biol. Chem. 269, 26830-26835]. These studies indicated that a conserved central region (residues 112-210) distinct from that containing the active-site cysteine residue Cys(68) was important in determining NAT substrate selectivity. In the present study we have refined our analysis through further chimaera generation of this conserved region and by subsequent site-directed mutagenesis of individual amino acids. Enzyme-kinetic analysis of these mutant proteins with the NAT1-selective and NAT2-selective substrates p-aminosalicylic acid (PAS) and sulphamethazine (SMZ) respectively suggests that residues 125, 127 and 129 are important determinants of NAT1-type and NAT2-type substrate selectivity. Modification of Arg(127) had the greatest effect on specificity for PAS, whereas changing Phe(125) had the greatest effect on specificity for SMZ. Selected NAT mutants exhibited K(m) values for acetyl-CoA that were comparable with those of the wild-type NATs, implying that the mutations affected acceptor substrate specificity rather than cofactor binding affinity. Taken together with previous observations, these results suggest that residues 125, 127 and 129 might contribute to the formation of the active-site pocket surrounding Cys(68) and function as important determinants of NAT substrate selectivity.

Full Text

The Full Text of this article is available as a PDF (265.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Badawi A. F., Stern S. J., Lang N. P., Kadlubar F. F. Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogen-DNA adduct levels and human cancer susceptibility. Prog Clin Biol Res. 1996;395:109–140. [PubMed] [Google Scholar]
  2. Barski O. A., Gabbay K. H., Bohren K. M. The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity. Biochemistry. 1996 Nov 12;35(45):14276–14280. doi: 10.1021/bi9619740. [DOI] [PubMed] [Google Scholar]
  3. Blum M., Grant D. M., McBride W., Heim M., Meyer U. A. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol. 1990 Apr;9(3):193–203. doi: 10.1089/dna.1990.9.193. [DOI] [PubMed] [Google Scholar]
  4. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  5. Cheon H. G., Hanna P. E. Effect of group-selective modification reagents on arylamine N-acetyltransferase activities. Biochem Pharmacol. 1992 May 28;43(10):2255–2268. doi: 10.1016/0006-2952(92)90185-l. [DOI] [PubMed] [Google Scholar]
  6. Cordes M. H., Walsh N. P., McKnight C. J., Sauer R. T. Evolution of a protein fold in vitro. Science. 1999 Apr 9;284(5412):325–328. doi: 10.1126/science.284.5412.325. [DOI] [PubMed] [Google Scholar]
  7. Deloménie C., Goodfellow G. H., Krishnamoorthy R., Grant D. M., Dupret J. M. Study of the role of the highly conserved residues Arg9 and Arg64 in the catalytic function of human N-acetyltransferases NAT1 and NAT2 by site-directed mutagenesis. Biochem J. 1997 Apr 1;323(Pt 1):207–215. doi: 10.1042/bj3230207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dupret J. M., Goodfellow G. H., Janezic S. A., Grant D. M. Structure-function studies of human arylamine N-acetyltransferases NAT1 and NAT2. Functional analysis of recombinant NAT1/NAT2 chimeras expressed in Escherichia coli. J Biol Chem. 1994 Oct 28;269(43):26830–26835. [PubMed] [Google Scholar]
  9. Dupret J. M., Grant D. M. Site-directed mutagenesis of recombinant human arylamine N-acetyltransferase expressed in Escherichia coli. Evidence for direct involvement of Cys68 in the catalytic mechanism of polymorphic human NAT2. J Biol Chem. 1992 Apr 15;267(11):7381–7385. [PubMed] [Google Scholar]
  10. Grant D. M., Blum M., Beer M., Meyer U. A. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol. 1991 Feb;39(2):184–191. [PubMed] [Google Scholar]
  11. Grant D. M., Lottspeich F., Meyer U. A. Evidence for two closely related isozymes of arylamine N-acetyltransferase in human liver. FEBS Lett. 1989 Feb 13;244(1):203–207. doi: 10.1016/0014-5793(89)81193-7. [DOI] [PubMed] [Google Scholar]
  12. Grant D. M., Mörike K., Eichelbaum M., Meyer U. A. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest. 1990 Mar;85(3):968–972. doi: 10.1172/JCI114527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hein D. W., Doll M. A., Rustan T. D., Gray K., Feng Y., Ferguson R. J., Grant D. M. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis. 1993 Aug;14(8):1633–1638. doi: 10.1093/carcin/14.8.1633. [DOI] [PubMed] [Google Scholar]
  14. Hughes N. C., Janezic S. A., McQueen K. L., Jewett M. A., Castranio T., Bell D. A., Grant D. M. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. Pharmacogenetics. 1998 Feb;8(1):55–66. doi: 10.1097/00008571-199802000-00008. [DOI] [PubMed] [Google Scholar]
  15. Kadowaki H., Kadowaki T., Wondisford F. E., Taylor S. I. Use of polymerase chain reaction catalyzed by Taq DNA polymerase for site-specific mutagenesis. Gene. 1989 Mar 15;76(1):161–166. doi: 10.1016/0378-1119(89)90018-8. [DOI] [PubMed] [Google Scholar]
  16. Matas N., Thygesen P., Stacey M., Risch A., Sim E. Mapping AAC1, AAC2 and AACP, the genes for arylamine N-acetyltransferases, carcinogen metabolising enzymes on human chromosome 8p22, a region frequently deleted in tumours. Cytogenet Cell Genet. 1997;77(3-4):290–295. doi: 10.1159/000134601. [DOI] [PubMed] [Google Scholar]
  17. Merickel A., Kaback H. R., Edwards R. H. Charged residues in transmembrane domains II and XI of a vesicular monoamine transporter form a charge pair that promotes high affinity substrate recognition. J Biol Chem. 1997 Feb 28;272(9):5403–5408. doi: 10.1074/jbc.272.9.5403. [DOI] [PubMed] [Google Scholar]
  18. Vallette F., Mege E., Reiss A., Adesnik M. Construction of mutant and chimeric genes using the polymerase chain reaction. Nucleic Acids Res. 1989 Jan 25;17(2):723–733. doi: 10.1093/nar/17.2.723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Vatsis K. P., Weber W. W., Bell D. A., Dupret J. M., Evans D. A., Grant D. M., Hein D. W., Lin H. J., Meyer U. A., Relling M. V. Nomenclature for N-acetyltransferases. Pharmacogenetics. 1995 Feb;5(1):1–17. doi: 10.1097/00008571-199502000-00001. [DOI] [PubMed] [Google Scholar]
  20. Vaughan C. K., Buckle A. M., Fersht A. R. Structural response to mutation at a protein-protein interface. J Mol Biol. 1999 Mar 12;286(5):1487–1506. doi: 10.1006/jmbi.1998.2559. [DOI] [PubMed] [Google Scholar]
  21. Watanabe M., Sofuni T., Nohmi T. Involvement of Cys69 residue in the catalytic mechanism of N-hydroxyarylamine O-acetyltransferase of Salmonella typhimurium. Sequence similarity at the amino acid level suggests a common catalytic mechanism of acetyltransferase for S. typhimurium and higher organisms. J Biol Chem. 1992 Apr 25;267(12):8429–8436. [PubMed] [Google Scholar]
  22. Wuytens G., Verschueren K., de Winter J. P., Gajendran N., Beek L., Devos K., Bosman F., de Waele P., Andries M., van den Eijnden-van Raaij A. J. Identification of two amino acids in activin A that are important for biological activity and binding to the activin type II receptors. J Biol Chem. 1999 Apr 2;274(14):9821–9827. doi: 10.1074/jbc.274.14.9821. [DOI] [PubMed] [Google Scholar]
  23. Zhang X. J., Baase W. A., Shoichet B. K., Wilson K. P., Matthews B. W. Enhancement of protein stability by the combination of point mutations in T4 lysozyme is additive. Protein Eng. 1995 Oct;8(10):1017–1022. doi: 10.1093/protein/8.10.1017. [DOI] [PubMed] [Google Scholar]
  24. du Souich P., McLean A. J., Stoeckel K., Ohlendorf D., Gibaldi M. Screening methods using sulfamethazine for determining acetylator phenotype. Clin Pharmacol Ther. 1979 Dec;26(6):757–765. doi: 10.1002/cpt1979266757. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES